Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system.

Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

BAY-069 is a potent dual inhibitor of BCAT1/2 (branched-chain amino acid transaminases), with IC50 values of 31 nM for BCAT1 and 153 nM for BCAT2. It demonstrates high cellular activity, excellent selectivity, and is used as an in vitro probe.

Artemisitene, a natural derivative of Artemisinin, is a Nrf2 activator with antioxidant and anticancer activities. Artemisitene activates Nrf2 by decreasing Nrf2 ubiquitination and increasing its stability.

BAY-069 is a potent dual inhibitor of BCAT1/2 (branched-chain amino acid transaminases), with IC50 values of 31 nM for BCAT1 and 153 nM for BCAT2. It demonstrates high cellular activity, excellent selectivity, and is used as an in vitro probe.

BAY-069 is a potent dual inhibitor of BCAT1/2 (branched-chain amino acid transaminases), with IC50 values of 31 nM for BCAT1 and 153 nM for BCAT2. It demonstrates high cellular activity, excellent selectivity, and is used as an in vitro probe.

BAY-069 is a potent dual inhibitor of BCAT1/2 (branched-chain amino acid transaminases), with IC50 values of 31 nM for BCAT1 and 153 nM for BCAT2. It demonstrates high cellular activity, excellent selectivity, and is used as an in vitro probe.

JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders.

JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders.